Skip to content

Study · Randomized controlled trial · 2026

2 results

Biological modulators of treatment outcome during psychiatric care: The interplay between inflammation and oxytocin.

Sedoff O, Brugnera A, Tasca GA, Maoz H, Bloch Y, Tzur Bitan D

Psychoneuroendocrinology14 May 2026

PMID42156189 (opens in a new tab)DOI10.1016/j.psyneuen.2026.107894 (opens in a new tab)PepBankPUB-42156189
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In inpatients with high baseline neutrophil-to-lymphocyte ratio, intranasal oxytocin did not significantly improve depression outcomes versus placebo.

    In plain wordsIn psychiatric inpatients with high inflammation, oxytocin nose spray did not significantly improve depression more than placebo.

    Peptide
    Oxytocin
    Outcome
    No significant changeDepression improvement in patients with high baseline NLR
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    Dose not stated · intranasal · four weeksAs given in this study (human).

    Source sentences

    Summary
    indicating that OT administration did not significantly improve depression outcomes for patients with high baseline NLR (p = .35)
    1 context sentence
    Summary · context
    Patients (N = 72, 76% females) who received intranasal OT or placebo twice daily for four weeks adjacent to standard inpatient care were examined for their pre-treatment inflammation, using the neutrophil-to-lymphocyte ratio (NLR).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In inpatients with low baseline neutrophil-to-lymphocyte ratio, intranasal oxytocin was associated with greater improvement in depression than placebo.

    In plain wordsIn psychiatric inpatients with low inflammation, oxytocin nose spray was linked to greater improvement in depression than placebo.

    Peptide
    Oxytocin
    Outcome
    DecreaseDepression improvement in patients with low baseline NLR
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    Dose not stated · intranasal · four weeksAs given in this study (human).

    Source sentences

    Summary
    but was associated with greater improvement among patients with low baseline NLR compared to placebo (p = .001).
    1 context sentence
    Summary · context
    Patients (N = 72, 76% females) who received intranasal OT or placebo twice daily for four weeks adjacent to standard inpatient care were examined for their pre-treatment inflammation, using the neutrophil-to-lymphocyte ratio (NLR).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:50 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.